Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eisai’s Lenvima Gets CHMP Backing, Nexavar Marketing Rivalry Looms

This article was originally published in The Pink Sheet Daily

Executive Summary

Other medicines receiving positive opinions from the EU’s top scientific advisory panel after its March meeting include Helsinn’s Akynzeo for chemotherapy associated nausea and vomiting, the first 9-valent HPV vaccine, Sanofi Pasteur MSD’s Gardasil 9, and Boehringer Ingelheim’s Synjardy combination of empagliflozin and metformin.

You may also be interested in...



Eisai’s Lenvima Will Face Off Against Nexavar In Thyroid Cancer

Approved two months early, tyrosine kinase inhibitor’s labeling reflects 14.7-month progression-free survival improvement in patients with differentiated thyroid cancer, almost triple the benefit seen with Bayer/Amgen’s sorafenib.

Merck’s Gardasil Adds Serotypes; Boosting Vaccinations Seems Bigger Challenge

Promotion strategy likely to remain same after nine-valent HPV vaccine wins FDA approval; Merck may need help from the CDC to overcome cultural barriers to adoption.

Ipsen Strengthens Early Clinical Pipeline With IRLAB’s Mesdepotem For Levodopa-Induced Dyskinesia

Ipsen has gained worldwide development and commercialization rights to IRLAB’s dopamine D3 antagonist, mesdepotem, in levodopa-induced dyskinesia in Parkinson’s disease.

Topics

Related Companies

UsernamePublicRestriction

Register

PS078310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel